Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Pierre J. Ferré"'
Autor:
Noureddine Loukili, Isabelle Vandenberghe, Olivier Delfour, Françoise Fraboul, Eric Chetaille, Francisco Cruzalegui, Nathalie Corvaïa, Pierre J. Ferré
Publikováno v:
Cancer Research. 79:2400-2400
VISTA (V-domain Ig suppressor of T cell activation), also known as PD-1 homolog (PD-1H), is a transmembrane protein which is highly expressed in myeloid cells such as neutrophils, monocytes, macrophages, and dendritic cells, and at low levels on naiv
Autor:
MyTrang Nguyen, Jérôme Besse, John N. Snouwaert, Leigh A. Jania, Pierre J. Ferré, Beverly H. Koller, Barbara Akla, Pragnya Dontu
Publikováno v:
Cancer Research. 79:503-503
Prostaglandins are lipid autacoids derived from arachidonic acid (AA). AA released from the cell membrane is metabolized by the sequential actions of prostaglandin G/H synthase or cyclooxygenase (COX) and respective synthases, such as mPGES-1, which
Autor:
Pierre-Louis Toutain, François Hatey, Pierre J. Ferré, Magali SanCristobal, Agnès Bonnet, Gwenola Tosser-Klopp, Laurence Liaubet, Didier Concordet, Emmanuelle Uro-Coste, Hervé P. Lefebvre
Publikováno v:
Pharmaceutical Research
Pharmaceutical Research, American Association of Pharmaceutical Scientists, 2007, 24 (8), pp.1480-9. ⟨10.1007/s11095-007-9266-8⟩
Pharmaceutical Research, 2007, 24 (8), pp.1480-9. ⟨10.1007/s11095-007-9266-8⟩
Pharmaceutical Research / Pharmaceutical Research (Dordrecht)
Pharmaceutical Research / Pharmaceutical Research (Dordrecht), 2007, 24 (8), pp.1480-9. ⟨10.1007/s11095-007-9266-8⟩
Pharmaceutical Research, American Association of Pharmaceutical Scientists, 2007, 24 (8), pp.1480-9. ⟨10.1007/s11095-007-9266-8⟩
Pharmaceutical Research, 2007, 24 (8), pp.1480-9. ⟨10.1007/s11095-007-9266-8⟩
Pharmaceutical Research / Pharmaceutical Research (Dordrecht)
Pharmaceutical Research / Pharmaceutical Research (Dordrecht), 2007, 24 (8), pp.1480-9. ⟨10.1007/s11095-007-9266-8⟩
International audience; PURPOSE: The purpose of this study is to describe the time course of gene expression in a skeletal muscle local injury induced by an intramuscular (IM) injection, and to compare the dynamics of gene expression with pathologica
Autor:
Pierre-Louis Toutain, J. P. Braun, Hervé P. Lefebvre, Pierre J. Ferré, J. Cazaux, Valérie Laroute
Publikováno v:
Journal of Animal Science. 84:1295-1301
Evaluation of skeletal muscle tolerance during development of new drug formulations for i.m. use is most often based on terminal methods performed in the target species after slaughtering. The objective of this study was to evaluate the effect of mus
Autor:
Pierre J. Ferré, Hervé P. Lefebvre, Valérie Laroute, Guillaume Chanoit, Martial Manesse, Didier Concordet, Jean-Pierre Ferré
Publikováno v:
American Journal of Veterinary Research. 62:1698-1705
Objectives—To investigate and validate noninvasive methods for the quantitative evaluation of postinjection muscle damage. Animals—5 adult sheep. Procedures—Muscle lesions were induced twice in the lumbar region of the longissimus dorsi muscles
Publikováno v:
Interactive Cardiovascular and Thoracic Surgery
Interactive Cardiovascular and Thoracic Surgery, Oxford University Press (OUP), 2007, 6 (6), pp.705-707
Interactive Cardiovascular and Thoracic Surgery, Oxford University Press (OUP), 2007, 6 (6), pp.705-707
We describe a chronic model of lymphatico-venous bypass in pigs with emphasis to surgical considerations, major per- and postoperative complications. A catheter (silicone or heparin coated polyurethane) was inserted in the thoracic duct of nine pigs
Autor:
Millagahamanda G Ranasinghe, Hervé P. Lefebvre, Qiang Li, Kirby Pasloske, Ted Whittem, Pierre J Ferré
Publikováno v:
Veterinary Anaesthesia and Analgesia
Veterinary Anaesthesia and Analgesia, Wiley, 2006, 33 (4), pp.229-236. ⟨10.1111/j.1467-2995.2005.00264.x⟩
Veterinary Anaesthesia and Analgesia, Wiley, 2006, 33 (4), pp.229-236. ⟨10.1111/j.1467-2995.2005.00264.x⟩
Objective To determine the pharmacokinetic parameters of alfaxalone in dogs after the intravenous (IV) administration of clinical and supra-clinical doses of a 2-hydroxypropyl-beta-cyclodextrin (HPCD) alfaxalone formulation (Alfaxan-CD RTU). Experime